The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
IFN λ is a potent anti‐influenza therapeutic without the inflammatory side effects of IFN α treatment
Open accessAbstract
Influenza A virus ( IAV )‐induced severe disease is characterized by infected lung epithelia, robust inflammatory responses and acute lung injury. Since type I interferon ( IFN αβ) and type III interferon ( IFN λ) are potent antiviral cytokines with immunomodulatory potential, we assessed their efficacy as IAV treatments. IFN λ treatment of IAV ‐infected Mx1‐positive mice lowered viral load and protected from disease. IFN α treatment also restricted IAV replication but exacerbated disease. IFN α treatment increased pulmonary proinflammatory cytokine secretion, innate cell recruitment and epithelial cell death, unlike IFN λ‐treatment. IFN λ lacked the direct stimulatory activity of IFN α on immune cells. In epithelia, both IFN s induced antiviral genes but no inflammatory cytokines. Similarly, human airway epithelia responded to both IFN α and IFN λ by induction of antiviral genes but not of cytokines, while hPBMC s responded only to IFN α. The restriction of both IFN λ responsiveness and productive IAV replication to pulmonary epithelia allows IFN λ to limit IAV spread through antiviral gene induction in relevant cells without overstimulating the immune system and driving immunopathology. We propose IFN λ as a non‐inflammatory and hence superior treatment option for human IAV infection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia.
de Jong, M. D., Simmons, C. P., Thanh, T. T., Hien, V. M., Smith, G. J. D., Chau, T. N. B., Hoang, D. M., Van Vinh Chau, N., Khanh, T. H., Dong, V. C., et al. (2006) · Nature Medicine · doi:10.1038/nm1477 · Cited by 1,858
Aberrant innate immune response in lethal infection of macaques with the 1918 influenza virus.
Kobasa, D., Jones, S. M., Shinya, K., Kash, J. C., Copps, J., Ebihara, H., Hatta, Y., Hyun Kim, J., Halfmann, P., Hatta, M., et al. (2007) · Nature · doi:10.1038/nature05495 · Cited by 934
Re-emergence of fatal human influenza A subtype H5N1 disease
Peiris, J., Yu, W., Leung, C., Cheung, C., Ng, W., Nicholls, J., Ng, T., Chan, K., Lai, S., Lim, W., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)15595-5 · Cited by 812
Baskin, C. R., Bielefeldt-Ohmann, H., Tumpey, T. M., Sabourin, P. J., Long, J. P., García-Sastre, A., Tolnay, A.-E., Albrecht, R., Pyles, J. A., Olson, P. H., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813234106 · Cited by 361
Cited by
The pathogenesis and treatment of the `Cytokine Storm' in COVID-19
Ye, Q., Wang, B., & Mao, J. (2020) · Journal of Infection · doi:10.1016/j.jinf.2020.03.037 · Cited by 2,761
Channappanavar, R., & Perlman, S. (2017) · Seminars in Immunopathology · doi:10.1007/s00281-017-0629-x · Cited by 2,524
Sheahan, T. P., Sims, A. C., Leist, S. R., Schäfer, A., Won, J., Brown, A. J., Montgomery, S. A., Hogg, A., Babusis, D., Clarke, M. O., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-13940-6 · Cited by 1,738
Type I and Type III Interferons – Induction, Signaling, Evasion, and Application to Combat COVID-19
Park, A., & Iwasaki, A. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.05.008 · Cited by 909
A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures
Dinnon, K. H., Leist, S. R., Schäfer, A., Edwards, C. E., Martinez, D. R., Montgomery, S. A., West, A., Yount, B. L., Hou, Y. J., Adams, L. E., et al. (2020) · Nature · doi:10.1038/s41586-020-2708-8 · Cited by 675
Metadata
- Authors
- Davidson, S., McCabe, T. M., Crotta, S., Gad, H. H., Hessel, E. M., Beinke, S., Hartmann, R., & Wack, A.
- Venue
- EMBO Molecular Medicine
- Published
- 2016-08-12
- Volume
- 8
- Issue
- 9
- Pages
- 1099-1112
- ISSN
- 1757-4676 (ISSN-L)
- 1757-4684
- OpenAlex
- W2517547699
- Cited by
- 240
- References
- 4
- FWCI
- 8.41
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: IFN λ is a potent anti‐influenza therapeutic without the inflammatory side effects of IFN α treatment. https://app.cochat.ai/papers/10.15252/emmm.201606413
- The paper
- Davidson, S., McCabe, T. M., Crotta, S., Gad, H. H., Hessel, E. M., Beinke, S., Hartmann, R., & Wack, A. (2016). IFN λ is a potent anti‐influenza therapeutic without the inflammatory side effects of IFN α treatment. EMBO Molecular Medicine. https://doi.org/10.15252/emmm.201606413
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.